Physician profile
Jan Seiler
NPI 1336252337
$2,919.58
in general payments reported to CMS, 2019-2025
23 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $413 · 2022: $1,196 · 2023: $1,119 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,051.11 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $455.51 | 2022-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $439.11 | 2021-2023 | Xifaxan, Trulance, Plenvu |
| Merck Sharp & Dohme LLC | $123.06 | 2022-2023 | Dificid, Zinplava |
| Janssen Biotech, INC. | $105.23 | 2021-2023 | Simponi, Simponi Aria, Remicade |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $103.40 | 2025 | |
| Ironwood Pharmaceuticals, INC | $99.45 | 2022-2023 | Linzess |
| Astrazeneca Pharmaceuticals LP | $89.03 | 2025 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $85.15 | 2022-2023 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $72.38 | 2022-2023 | Dupixent |
| Amgen INC. | $51.69 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $32.62 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $32.60 | 2022 | |
| Ardelyx, INC. | $28.80 | 2023 | Ibsrela |
| Daiichi Sankyo INC. | $24.73 | 2023 | Injectafer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.50 | 2023 | |
| Qol Medical, LLC | $19.54 | 2022 | |
| Gilead Sciences, INC. | $17.85 | 2023 | |
| Pfizer INC. | $16.99 | 2022 | |
| Fresenius Kabi USA, LLC | $14.61 | 2023 | Idacio |
| Organon LLC | $12.27 | 2023 | Renflexis |
| Braintree Laboratories, INC. | $11.85 | 2022 | |
| Redhill Biopharma INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Seiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.